<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649192</url>
  </required_header>
  <id_info>
    <org_study_id>FLUVIT</org_study_id>
    <nct_id>NCT02649192</nct_id>
  </id_info>
  <brief_title>Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study of Antibody Induction by Vitamin Supplementation at the Time of Influenza Virus Vaccinations in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children are particularly vulnerable to respiratory virus infections, especially influenza.
      Vitamin A &amp; D deficiencies are associated with vulnerability to infectious diseases of the
      respiratory tract. The central hypothesis of this protocol is that vitamin supplements will
      enhance antibody responses toward the flu vaccine in children. Children, 2-8 years old, will
      be randomized to receive influenza virus vaccine with a vitamin A+D supplement or influenza
      virus vaccine with placebo. Children will be tested for vitamin levels and immune responses
      before and after influenza virus vaccinations to determine if vitamin supplementation
      improves the influenza virus vaccine-induced immune response.

      PRIMARY OBJECTIVE:

        -  To assess the vaccine-induced and total antibody (including IgG and IgA) response after
           influenza virus vaccine administration and IgA/IgG plus IgA/IgM ratios at 28 and 56 days
           in sera

      SECONDARY OBJECTIVE:

        -  To assess the neutralizing response toward influenza virus vaccine in the sera.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to receive either an influenza virus vaccine plus Vitamins A
      &amp; D or an influenza virus vaccine plus placebo. They will be stratified based on retinol
      binding protein (RBP) levels at screening, using a cut-off indicative of Vitamin A
      insufficiency (≤22,000 ng/ml). Co-enrolled sibling participants will be first stratified by
      RBP levels, then siblings within the same stratum will be equally assigned to different arms
      to provide greater assurance of balanced treatment assignment. Children will be tested for
      vitamin levels and immune responses before and after influenza virus vaccinations to
      determine if vitamin supplementation improves the influenza virus vaccine-induced antibody
      immune response.

      All participants will receive two doses of an influenza virus vaccination administered at
      least 28 days apart. Vitamin levels and antibody responses toward the vaccine will be
      measured on day 0 (baseline levels obtained where day 0 equals the first influenza virus
      vaccination administration), day 28, and day 56. Placebo or Vitamins A + D (at the levels of
      20,000 IU and 2,000 IU, respectively) will be administered orally on the days of vaccination.

      Blood serum samples will be collected from participants on Day 0, prior to receiving
      influenza virus vaccine on Day 28, and during their Day 56 follow-up visit.

      Parents will be asked to fill out diary cards to indicate food intake for children during the
      study period along with an optional food frequency questionnaire given on day 56. Specific
      measurements on days 28, and 56 will include analyses of vaccine-specific and total IgA, IgG,
      and IgA/IgG plus IgA/IgM ratios in sera. Functional activities of antibodies toward influenza
      vaccine will also be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2016</start_date>
  <completion_date type="Actual">June 29, 2018</completion_date>
  <primary_completion_date type="Actual">June 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera</measure>
    <time_frame>Day 56 after vaccination</time_frame>
    <description>The percentage of 2X increases or conversion from undetectable to detectable response in virus-specific antibody toward any vaccine component after 2 immunizations in intervention and control groups will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Isotype Ratios on Day 56</measure>
    <time_frame>Day 56 after vaccination</time_frame>
    <description>Isotype ratios will be summarized with descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion at Day 56 After Vaccination, Overall</measure>
    <time_frame>Day 56 after vaccination</time_frame>
    <description>Secondary analyses will examine sero-conversion based on antibody functions (HAI or neutralization) defined as antibody titers of &lt;1:40 converting to ≥1:40, or a four-fold increase in titer for participants with a starting titer of ≥1:40. Sero-conversion rate (expressed as percentage) will be estimated with 95% confidence interval. The rate difference will be described with point estimate and 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion at Day 56 After Vaccination, by Vitamin A Levels at Screening</measure>
    <time_frame>Day 56 after vaccination</time_frame>
    <description>Secondary analyses will examine sero-conversion based on antibody functions (HAI or neutralization) defined as antibody titers of &lt;1:40 converting to ≥1:40, or a four-fold increase in titer for participants with a starting titer of ≥1:40. Sero-conversion rate (expressed as percentage) will be estimated with 95% confidence interval for participants sufficient and insufficient in vitamin A at screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI Titers at Day 56 After Vaccination, Overall</measure>
    <time_frame>Day 56 after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI Titers at Day 56 After Vaccination, by Vitamin A Levels at Screening</measure>
    <time_frame>Day 56 after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Influenza Virus Vaccine Plus Vitamins A and D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza Virus Vaccine Plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza virus vaccine</intervention_name>
    <description>Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.</description>
    <arm_group_label>Influenza Virus Vaccine Plus Placebo</arm_group_label>
    <arm_group_label>Influenza Virus Vaccine Plus Vitamins A and D</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamins A and D</intervention_name>
    <description>The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.</description>
    <arm_group_label>Influenza Virus Vaccine Plus Vitamins A and D</arm_group_label>
    <other_name>Nutritional Supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.</description>
    <arm_group_label>Influenza Virus Vaccine Plus Placebo</arm_group_label>
    <other_name>Look-alike Medication</other_name>
    <other_name>Matched Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resident of the Memphis area community.

          -  Parent or legal guardian willing and able to give informed consent and comply with
             study requirements.

        Exclusion Criteria:

          -  Current use of investigational or immunosuppressive drugs (e.g., steroids) at the time
             of enrollment.

          -  Currently taking a daily (routine) vitamin A, D, or multivitamin. Note: participants
             who report occasional or sporadic vitamin use will be allowed to enroll.

          -  History of lung disease, asthma, immunodeficiency, sickle cell disease, or any other
             serious underlying condition or disease in the opinion of the principal investigator.

          -  Evidence of developmental delay or evolving neurological disorders at screening.
             Current use of antibiotics or antivirals at enrollment.

          -  History of having a severe allergy to eggs or to any inactive ingredient in the
             influenza virus vaccine

          -  History of a life-threatening reaction to influenza vaccinations

          -  Currently wheezing at the time of enrollment

          -  History of heart, kidney, or lung conditions

          -  History of diabetes

          -  Use of an anti-influenza medication (including amantadine, rimantadine, oseltamivir,
             and zanamivir) within 14 days prior to enrollment

          -  Acute febrile [&gt;100.0°F (37.8°C) oral] illness or acute respiratory illness (e.g.,
             cough or sore throat) within 3 days prior to enrollment

          -  Previous receipt of current seasonal influenza vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nehali Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <results_first_submitted>June 25, 2019</results_first_submitted>
  <results_first_submitted_qc>August 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2019</results_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Vitamin Supplements</keyword>
  <keyword>Influenza virus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02649192/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A&amp;D – S1</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
        </group>
        <group group_id="P2">
          <title>Placebo – S1</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2015-16 season</description>
        </group>
        <group group_id="P3">
          <title>A&amp;D – S2</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
        </group>
        <group group_id="P4">
          <title>Placebo – S2</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2016-17 season</description>
        </group>
        <group group_id="P5">
          <title>A&amp;D – S3</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
        </group>
        <group group_id="P6">
          <title>Placebo – S3</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2017-18 season</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vitamin A Sufficiency (RBP≥22,000 ng/ml)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vitamin A Insufficiency (RBP&lt;22,000 ng/m</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A&amp;D-S1</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
        </group>
        <group group_id="B2">
          <title>Placebo – S1</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2015-16 season</description>
        </group>
        <group group_id="B3">
          <title>A&amp;D – S2</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
        </group>
        <group group_id="B4">
          <title>Placebo – S2</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2016-17 season</description>
        </group>
        <group group_id="B5">
          <title>A&amp;D – S3</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
        </group>
        <group group_id="B6">
          <title>Placebo – S3</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2017-18 season</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="14"/>
            <count group_id="B7" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="B2" value="3.5" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="B3" value="5" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="B4" value="4" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="B5" value="3" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="B6" value="5" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="B7" value="5" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera</title>
        <description>The percentage of 2X increases or conversion from undetectable to detectable response in virus-specific antibody toward any vaccine component after 2 immunizations in intervention and control groups will be reported.</description>
        <time_frame>Day 56 after vaccination</time_frame>
        <population>All enrolled subjects who satisfied the inclusion/exclusion criteria were included in the analysis. For the four participants who didn’t complete the study, results after one immunization were used.</population>
        <group_list>
          <group group_id="O1">
            <title>A&amp;D – S1</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
          </group>
          <group group_id="O2">
            <title>Placebo – S1</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2015-16 season</description>
          </group>
          <group group_id="O3">
            <title>A&amp;D – S2</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
          </group>
          <group group_id="O4">
            <title>Placebo – S2</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2016-17 season</description>
          </group>
          <group group_id="O5">
            <title>A&amp;D – S3</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
          </group>
          <group group_id="O6">
            <title>Placebo – S3</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2017-18 season</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera</title>
          <description>The percentage of 2X increases or conversion from undetectable to detectable response in virus-specific antibody toward any vaccine component after 2 immunizations in intervention and control groups will be reported.</description>
          <population>All enrolled subjects who satisfied the inclusion/exclusion criteria were included in the analysis. For the four participants who didn’t complete the study, results after one immunization were used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Isotype Ratios on Day 56</title>
        <description>Isotype ratios will be summarized with descriptive statistics.</description>
        <time_frame>Day 56 after vaccination</time_frame>
        <population>Subjects with complete isotype data at day 56. Subjects with an undetermined assay result were not included in analyses. In some cases, the limit of detection (LOD) for the assay was reached and that LOD value was used in calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>A&amp;D-S1</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
          </group>
          <group group_id="O2">
            <title>Placebo – S1</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2015-16 season</description>
          </group>
          <group group_id="O3">
            <title>A&amp;D – S2</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
          </group>
          <group group_id="O4">
            <title>Placebo – S2</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2016-17 season</description>
          </group>
          <group group_id="O5">
            <title>A&amp;D – S3</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
          </group>
          <group group_id="O6">
            <title>Placebo – S3</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2017-18 season</description>
          </group>
        </group_list>
        <measure>
          <title>Isotype Ratios on Day 56</title>
          <description>Isotype ratios will be summarized with descriptive statistics.</description>
          <population>Subjects with complete isotype data at day 56. Subjects with an undetermined assay result were not included in analyses. In some cases, the limit of detection (LOD) for the assay was reached and that LOD value was used in calculations.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA/IgG1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.06" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.22" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.004" upper_limit="0.63"/>
                    <measurement group_id="O4" value="0.27" lower_limit="0.13" upper_limit="0.47"/>
                    <measurement group_id="O5" value="0.21" lower_limit="0.13" upper_limit="0.65"/>
                    <measurement group_id="O6" value="0.28" lower_limit="0.12" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA/IgG2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="0.24" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.69" lower_limit="0.49" upper_limit="1.93"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.004" upper_limit="6.3"/>
                    <measurement group_id="O4" value="1.13" lower_limit="0.58" upper_limit="4.45"/>
                    <measurement group_id="O5" value="0.65" lower_limit="0.19" upper_limit="2.03"/>
                    <measurement group_id="O6" value="0.75" lower_limit="0.22" upper_limit="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA/IgG3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" lower_limit="0.38" upper_limit="7.75"/>
                    <measurement group_id="O2" value="3.03" lower_limit="1.55" upper_limit="7.44"/>
                    <measurement group_id="O3" value="1.44" lower_limit="0.02" upper_limit="6.97"/>
                    <measurement group_id="O4" value="1.68" lower_limit="0.29" upper_limit="5.13"/>
                    <measurement group_id="O5" value="2.4" lower_limit="0.89" upper_limit="12.5"/>
                    <measurement group_id="O6" value="3.02" lower_limit="0.41" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA/IgM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="0.16" upper_limit="2.8"/>
                    <measurement group_id="O2" value="1.37" lower_limit="0.83" upper_limit="2.89"/>
                    <measurement group_id="O3" value="1.21" lower_limit="0.03" upper_limit="3.06"/>
                    <measurement group_id="O4" value="1.21" lower_limit="0.45" upper_limit="2.88"/>
                    <measurement group_id="O5" value="0.86" lower_limit="0.23" upper_limit="1.9"/>
                    <measurement group_id="O6" value="1" lower_limit="0.14" upper_limit="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG1 at day 56 in 2015-16 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG1 at day 56 in 2016-17 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG1 at day 56 in 2017-18 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG2 at day 56 in 2015-16 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG2 at day 56 in 2016-17 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG2 at day 56 in 2017-18 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG3 at day 56 in 2015-16 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG3 at day 56 in 2016-17 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgG3 at day 56 in 2017-18 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgM at day 56 in 2015-16 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgM at day 56 in 2016-17 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between intervention and placebo groups in the ratio of IgA/IgM at day 56 in 2017-18 season</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion at Day 56 After Vaccination, Overall</title>
        <description>Secondary analyses will examine sero-conversion based on antibody functions (HAI or neutralization) defined as antibody titers of &lt;1:40 converting to ≥1:40, or a four-fold increase in titer for participants with a starting titer of ≥1:40. Sero-conversion rate (expressed as percentage) will be estimated with 95% confidence interval. The rate difference will be described with point estimate and 95% confidence interval.</description>
        <time_frame>Day 56 after vaccination</time_frame>
        <population>Subjects with complete HAI data at day 56. Subjects without a day 56 sample were not included in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A&amp;D-S1</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
          </group>
          <group group_id="O2">
            <title>Placebo – S1</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2015-16 season</description>
          </group>
          <group group_id="O3">
            <title>A&amp;D – S2</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
          </group>
          <group group_id="O4">
            <title>Placebo – S2</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2016-17 season</description>
          </group>
          <group group_id="O5">
            <title>A&amp;D – S3</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
          </group>
          <group group_id="O6">
            <title>Placebo – S3</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2017-18 season</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion at Day 56 After Vaccination, Overall</title>
          <description>Secondary analyses will examine sero-conversion based on antibody functions (HAI or neutralization) defined as antibody titers of &lt;1:40 converting to ≥1:40, or a four-fold increase in titer for participants with a starting titer of ≥1:40. Sero-conversion rate (expressed as percentage) will be estimated with 95% confidence interval. The rate difference will be described with point estimate and 95% confidence interval.</description>
          <population>Subjects with complete HAI data at day 56. Subjects without a day 56 sample were not included in analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O4" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                    <measurement group_id="O5" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                    <measurement group_id="O6" value="85.7" lower_limit="57.2" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="6.8" upper_limit="93.2"/>
                    <measurement group_id="O3" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O4" value="80.0" lower_limit="56.3" upper_limit="94.3"/>
                    <measurement group_id="O5" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="23.0" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="28.6" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O4" value="55.0" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O5" value="45.5" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O6" value="28.6" lower_limit="8.4" upper_limit="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="28.6" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O4" value="55.0" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O5" value="27.3" lower_limit="6.0" upper_limit="61.0"/>
                    <measurement group_id="O6" value="35.7" lower_limit="12.8" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H1N1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>H1N1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>-23.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.7</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>H1N1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>-13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.4</ci_lower_limit>
            <ci_upper_limit>26.5</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H3N2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>-10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.1</ci_lower_limit>
            <ci_upper_limit>56.1</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>H3N2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.8</ci_lower_limit>
            <ci_upper_limit>20.6</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>H3N2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>22.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.5</ci_lower_limit>
            <ci_upper_limit>57.9</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Phuket</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>B/Phuket</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>-26.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.1</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>B/Phuket</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>16.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.1</ci_lower_limit>
            <ci_upper_limit>53.3</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B/Brisbane</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>B/Brisbane</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>-26.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.1</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>B/Brisbane</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference in Seroconversion R</param_type>
            <param_value>-8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.4</ci_lower_limit>
            <ci_upper_limit>30.5</ci_upper_limit>
            <estimate_desc>Treatment group minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion at Day 56 After Vaccination, by Vitamin A Levels at Screening</title>
        <description>Secondary analyses will examine sero-conversion based on antibody functions (HAI or neutralization) defined as antibody titers of &lt;1:40 converting to ≥1:40, or a four-fold increase in titer for participants with a starting titer of ≥1:40. Sero-conversion rate (expressed as percentage) will be estimated with 95% confidence interval for participants sufficient and insufficient in vitamin A at screening.</description>
        <time_frame>Day 56 after vaccination</time_frame>
        <population>Subjects with complete HAI data at day 56. Subjects without a day 56 sample were not included in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A&amp;D-S1 VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S1 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
          </group>
          <group group_id="O2">
            <title>Placebo-S1 VAS</title>
            <description>Sub-group of subjects from the Placebo-S1 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus matched placebo in 2015-16 season</description>
          </group>
          <group group_id="O3">
            <title>A&amp;D-S2 VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S2 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
          </group>
          <group group_id="O4">
            <title>Placebo-S2 VAS</title>
            <description>Sub-group of subjects from the Placebo-S2 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus matched placebo in 2016-17 season</description>
          </group>
          <group group_id="O5">
            <title>A&amp;D-S3 VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S3 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
          </group>
          <group group_id="O6">
            <title>Placebo-S3 VAS</title>
            <description>Sub-group of subjects from the Placebo-S3 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus matched placebo in 2017-18 season</description>
          </group>
          <group group_id="O7">
            <title>A&amp;D-S1 Non-VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S1 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
          </group>
          <group group_id="O8">
            <title>Placebo-S1 Non-VAS</title>
            <description>Sub-group of subjects from the Placebo-S1 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus matched placebo in 2015-16 season</description>
          </group>
          <group group_id="O9">
            <title>A&amp;D-S2 Non-VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S2 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
          </group>
          <group group_id="O10">
            <title>Placebo-S2 Non-VAS</title>
            <description>Sub-group of subjects from the Placebo-S2 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus matched placebo in 2016-17 season</description>
          </group>
          <group group_id="O11">
            <title>A&amp;D-S3 Non-VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S3 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
          </group>
          <group group_id="O12">
            <title>Placebo-S3 Non-VAS</title>
            <description>Sub-group of subjects from the Placebo-S3 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus matched placebo in 2017-18 season</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion at Day 56 After Vaccination, by Vitamin A Levels at Screening</title>
          <description>Secondary analyses will examine sero-conversion based on antibody functions (HAI or neutralization) defined as antibody titers of &lt;1:40 converting to ≥1:40, or a four-fold increase in titer for participants with a starting titer of ≥1:40. Sero-conversion rate (expressed as percentage) will be estimated with 95% confidence interval for participants sufficient and insufficient in vitamin A at screening.</description>
          <population>Subjects with complete HAI data at day 56. Subjects without a day 56 sample were not included in analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O4" value="100" lower_limit="71.5" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="59.0" upper_limit="100"/>
                    <measurement group_id="O6" value="87.5" lower_limit="47.3" upper_limit="99.7"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O9" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O10" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O11" value="25.0" lower_limit="0.6" upper_limit="80.6"/>
                    <measurement group_id="O12" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="84.2"/>
                    <measurement group_id="O2" value="100" lower_limit="15.8" upper_limit="100"/>
                    <measurement group_id="O3" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                    <measurement group_id="O4" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O5" value="71.4" lower_limit="29.0" upper_limit="96.3"/>
                    <measurement group_id="O6" value="37.5" lower_limit="8.5" upper_limit="75.5"/>
                    <measurement group_id="O7" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="84.2"/>
                    <measurement group_id="O9" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O10" value="66.7" lower_limit="29.9" upper_limit="92.5"/>
                    <measurement group_id="O11" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O12" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="45.5" lower_limit="16.7" upper_limit="76.6"/>
                    <measurement group_id="O4" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                    <measurement group_id="O5" value="42.9" lower_limit="9.9" upper_limit="81.6"/>
                    <measurement group_id="O6" value="25.0" lower_limit="3.2" upper_limit="65.1"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O9" value="10.0" lower_limit="0.3" upper_limit="44.5"/>
                    <measurement group_id="O10" value="33.3" lower_limit="7.5" upper_limit="70.1"/>
                    <measurement group_id="O11" value="50.0" lower_limit="6.8" upper_limit="93.2"/>
                    <measurement group_id="O12" value="33.3" lower_limit="4.3" upper_limit="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="36.4" lower_limit="10.9" upper_limit="69.2"/>
                    <measurement group_id="O4" value="63.6" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O5" value="42.9" lower_limit="9.9" upper_limit="81.6"/>
                    <measurement group_id="O6" value="50.0" lower_limit="15.7" upper_limit="84.3"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O9" value="20.0" lower_limit="2.5" upper_limit="55.6"/>
                    <measurement group_id="O10" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                    <measurement group_id="O11" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O12" value="16.7" lower_limit="0.4" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAI Titers at Day 56 After Vaccination, Overall</title>
        <time_frame>Day 56 after vaccination</time_frame>
        <population>Subjects with complete HAI data at day 56. Subjects without a day 56 sample were not included in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A&amp;D-S1</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
          </group>
          <group group_id="O2">
            <title>Placebo – S1</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2015-16 season</description>
          </group>
          <group group_id="O3">
            <title>A&amp;D – S2</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
          </group>
          <group group_id="O4">
            <title>Placebo – S2</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2016-17 season</description>
          </group>
          <group group_id="O5">
            <title>A&amp;D – S3</title>
            <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
          </group>
          <group group_id="O6">
            <title>Placebo – S3</title>
            <description>Participants receiving influenza virus vaccine plus matched placebo in 2017-18 season</description>
          </group>
        </group_list>
        <measure>
          <title>HAI Titers at Day 56 After Vaccination, Overall</title>
          <population>Subjects with complete HAI data at day 56. Subjects without a day 56 sample were not included in analyses.</population>
          <units>titers</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="320"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="640" lower_limit="5" upper_limit="2560"/>
                    <measurement group_id="O4" value="640" lower_limit="160" upper_limit="2560"/>
                    <measurement group_id="O5" value="905" lower_limit="40" upper_limit="5120"/>
                    <measurement group_id="O6" value="1280" lower_limit="80" upper_limit="10240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" lower_limit="5" upper_limit="1280"/>
                    <measurement group_id="O2" value="480" lower_limit="160" upper_limit="1280"/>
                    <measurement group_id="O3" value="1810" lower_limit="40" upper_limit="20480"/>
                    <measurement group_id="O4" value="1093" lower_limit="5" upper_limit="5120"/>
                    <measurement group_id="O5" value="640" lower_limit="80" upper_limit="2560"/>
                    <measurement group_id="O6" value="960" lower_limit="5" upper_limit="5120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="80"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="160"/>
                    <measurement group_id="O4" value="40" lower_limit="5" upper_limit="320"/>
                    <measurement group_id="O5" value="5" lower_limit="5" upper_limit="113.14"/>
                    <measurement group_id="O6" value="5" lower_limit="5" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="2560"/>
                    <measurement group_id="O4" value="40" lower_limit="5" upper_limit="320"/>
                    <measurement group_id="O5" value="5" lower_limit="5" upper_limit="452.55"/>
                    <measurement group_id="O6" value="42.5" lower_limit="5" upper_limit="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAI Titers at Day 56 After Vaccination, by Vitamin A Levels at Screening</title>
        <time_frame>Day 56 after vaccination</time_frame>
        <population>Subjects with complete HAI data at day 56. Subjects without a day 56 sample were not included in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>A&amp;D-S1 VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S1 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
          </group>
          <group group_id="O2">
            <title>Placebo-S1 VAS</title>
            <description>Sub-group of subjects from the Placebo-S1 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus matched placebo in 2015-16 season</description>
          </group>
          <group group_id="O3">
            <title>A&amp;D-S2 VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S2 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
          </group>
          <group group_id="O4">
            <title>Placebo-S2 VAS</title>
            <description>Sub-group of subjects from the Placebo-S2 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus matched placebo in 2016-17 season</description>
          </group>
          <group group_id="O5">
            <title>A&amp;D-S3 VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S3 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
          </group>
          <group group_id="O6">
            <title>Placebo-S3 VAS</title>
            <description>Sub-group of subjects from the Placebo-S3 group, vitamin A sufficient (VAS), who received influenza virus vaccine plus matched placebo in 2017-18 season</description>
          </group>
          <group group_id="O7">
            <title>A&amp;D-S1 Non-VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S1 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
          </group>
          <group group_id="O8">
            <title>Placebo-S1 Non-VAS</title>
            <description>Sub-group of subjects from the Placebo-S1 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus matched placebo in 2015-16 season</description>
          </group>
          <group group_id="O9">
            <title>A&amp;D-S2 Non-VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S2 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
          </group>
          <group group_id="O10">
            <title>Placebo-S2 Non-VAS</title>
            <description>Sub-group of subjects from the Placebo-S2 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus matched placebo in 2016-17 season</description>
          </group>
          <group group_id="O11">
            <title>A&amp;D-S3 Non-VAS</title>
            <description>Sub-group of subjects from the A&amp;D-S3 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
          </group>
          <group group_id="O12">
            <title>Placebo-S3 Non-VAS</title>
            <description>Sub-group of subjects from the Placebo-S3 group, vitamin A insufficient/deficient (non-VAS), who received influenza virus vaccine plus matched placebo in 2017-18 season</description>
          </group>
        </group_list>
        <measure>
          <title>HAI Titers at Day 56 After Vaccination, by Vitamin A Levels at Screening</title>
          <population>Subjects with complete HAI data at day 56. Subjects without a day 56 sample were not included in analyses.</population>
          <units>titers</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="640" lower_limit="80" upper_limit="1280"/>
                    <measurement group_id="O4" value="640" lower_limit="160" upper_limit="2560"/>
                    <measurement group_id="O5" value="1280" lower_limit="40" upper_limit="5120"/>
                    <measurement group_id="O6" value="640" lower_limit="80" upper_limit="10240"/>
                    <measurement group_id="O7" value="5" lower_limit="5" upper_limit="320"/>
                    <measurement group_id="O8" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O9" value="640" lower_limit="5" upper_limit="2560"/>
                    <measurement group_id="O10" value="640" lower_limit="160" upper_limit="2560"/>
                    <measurement group_id="O11" value="640" lower_limit="640" upper_limit="3620.4"/>
                    <measurement group_id="O12" value="1920" lower_limit="1280" upper_limit="2560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200" lower_limit="80" upper_limit="320"/>
                    <measurement group_id="O2" value="720" lower_limit="160" upper_limit="1280"/>
                    <measurement group_id="O3" value="1810" lower_limit="160" upper_limit="20480"/>
                    <measurement group_id="O4" value="1280" lower_limit="160" upper_limit="5120"/>
                    <measurement group_id="O5" value="2560" lower_limit="160" upper_limit="2560"/>
                    <measurement group_id="O6" value="320" lower_limit="5" upper_limit="3620.4"/>
                    <measurement group_id="O7" value="320" lower_limit="5" upper_limit="1280"/>
                    <measurement group_id="O8" value="480" lower_limit="320" upper_limit="640"/>
                    <measurement group_id="O9" value="1545" lower_limit="40" upper_limit="2560"/>
                    <measurement group_id="O10" value="640" lower_limit="5" upper_limit="2560"/>
                    <measurement group_id="O11" value="400" lower_limit="80" upper_limit="1280"/>
                    <measurement group_id="O12" value="1920" lower_limit="640" upper_limit="5120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="5" upper_limit="80"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="80"/>
                    <measurement group_id="O4" value="80" lower_limit="5" upper_limit="320"/>
                    <measurement group_id="O5" value="5" lower_limit="5" upper_limit="113.14"/>
                    <measurement group_id="O6" value="5" lower_limit="5" upper_limit="160"/>
                    <measurement group_id="O7" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O8" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O9" value="5" lower_limit="5" upper_limit="160"/>
                    <measurement group_id="O10" value="5" lower_limit="5" upper_limit="80"/>
                    <measurement group_id="O11" value="42.5" lower_limit="5" upper_limit="80"/>
                    <measurement group_id="O12" value="42.5" lower_limit="5" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="640"/>
                    <measurement group_id="O4" value="40" lower_limit="5" upper_limit="320"/>
                    <measurement group_id="O5" value="80" lower_limit="5" upper_limit="452.55"/>
                    <measurement group_id="O6" value="80" lower_limit="5" upper_limit="640"/>
                    <measurement group_id="O7" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O8" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O9" value="5" lower_limit="5" upper_limit="2560"/>
                    <measurement group_id="O10" value="5" lower_limit="5" upper_limit="320"/>
                    <measurement group_id="O11" value="5" lower_limit="5" upper_limit="226.27"/>
                    <measurement group_id="O12" value="5" lower_limit="5" upper_limit="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 days after the final participant was dosed on Day 0.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A&amp;D-S1</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2015-16 season</description>
        </group>
        <group group_id="E2">
          <title>Placebo – S1</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2015-16 season</description>
        </group>
        <group group_id="E3">
          <title>A&amp;D – S2</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2016-17 season</description>
        </group>
        <group group_id="E4">
          <title>Placebo – S2</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2016-17 season</description>
        </group>
        <group group_id="E5">
          <title>A&amp;D – S3</title>
          <description>Participants receiving influenza virus vaccine plus vitamin A and D supplements in 2017-18 season</description>
        </group>
        <group group_id="E6">
          <title>Placebo – S3</title>
          <description>Participants receiving influenza virus vaccine plus matched placebo in 2017-18 season</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial trauma/fractured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Left forearm bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nehali Patel, MD</name_or_title>
      <organization>St. Jude Children's Research Hospital</organization>
      <phone>866-278-5833</phone>
      <email>info@stjude.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

